Photo of Andrew N. WeberPhoto of Andrew N. Weber

Andrew N. Weber



Michigan State University College of Law, J.D.
  • Jurisprudence Award in Advanced Criminal Procedure
  • Moot Court, Board Member, 2002-2003; Inns of the American Court, 2002-2003
University of Chicago, M.S.
  • Organic Chemistry
Eastern Michigan University, B.S.
  • Chemistry

Prior Employment

  • Miller, Canfield, Paddock and Stone, P.L.C.
  • Warner Lambert (now Pfizer, Inc.)
  • Aastrom Biosciences, Inc.
  • Dow Chemical Company

Bar Admissions

Court Admissions

Professional Affiliations

State Bar of Michigan

American Intellectual Property Law Association

American Bar Association

  • Intellectual Property Section

Materials Research Society

News & Resources


Andrew Weber is a partner in our Kalamazoo office. He counsels and represents clients on a wide range of intellectual property matters, dealing in particular with IP transactions including licensing and development agreements, due diligence, and patent procurement, trademarks, trade secrets, copyrights, and supporting IP litigation. He is especially experienced in matters involving chemical and energy technologies, and his background includes having worked at a Pfizer predecessor company and Dow Chemical.

  • Assists clients with technology transactions including acquisitions, partnering, licensing, and joint development transactions.
  • Assists clients in developing and implementing patent life-cycle management strategies, conducting IP due diligence, negotiating and drafting technology license agreements, and rendering legal opinions on patent validity and non-infringement
  • Drafts and prosecutes patent applications in a variety of technical areas, such as electrochemistry, agricultural science, inorganic and polymer chemistries, material science, nanotechnology, pharmaceuticals, and mechanical engineering
  • Assists clients in managing worldwide prosecution of patent applications
  • Represents clients in energy, environmental, pharmaceutical, agricultural, medical device, and automotive industries as well as academic institutions
  • Manages and conducts due diligence reviews in merger and acquisition transactions for companies investing in battery technologies
  • Counsels small and medium-sized battery companies looking for capital investment
  • Advises university spin-offs in energy and chemical technologies


  • Represented a multinational pharmaceutical company in a commercial development agreement for a small molecule drug candidate under clinical development, managed all IP matters associated with the commercialization efforts, and coordinated patent strategy between the agreement stakeholders.
  • Created and implemented a multi-tiered, platform technology licensing strategy for a pharmaceutical start-up.
  • Represented battery companies developing rechargeable battery technologies
  • Represented a pharmaceutical start-up company developing small molecule and biologic pharmaceuticals
  • Advised a multinational pharmaceutical company in developing a global patent strategy for a Phase II drug candidate, which involved obtaining patent issuances on the drug substance and implementing a patent life-cycle management plan
  • Drafted and negotiated a variety of agreements, including technology licensing, co-development and commercialization, contract manufacturing, supply, material transfer, nondisclosure, and clinical trial agreements
  • Conducted intellectual property due diligence for venture fund clients regarding potential investments, large pharmaceutical and biotechnology corporations regarding potential asset purchases and mergers, and start-up companies regarding potential licensing of university or third-party owned technologies
  • Obtained numerous U.S. Patents, including:
    • S. Patent No. 8,802,304: Bifunctional (rechargeable) air electrodes comprising a corrosion-resistant outer layer and conductive inner layer
    • S. Patent No. D586,739: Battery housing
    • S. Patent No. D586,738: Battery housing
    • S. Patent No. 7,488,558: Homogeneous separator
    • S. Patent No. 8,278,297: Protein kinase inhibitors
    • S. Patent No. 8,277,783: Permanganate containing whitening compositions and methods of their use
    • S. Patent No. 8,252,787: Protein kinase inhibitors
    • S. Patent No. 8,247,421: 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
    • S. Patent No. 8,188,281: Azaindoles useful as inhibitors of JAK and other protein kinases
    • S. Patent No. 8,163,917: Azaindoles useful as inhibitors of Janus kinases
    • S. Patent No. 8,129,387: Substituted 5,6-dihydroimidazo [1,5-F] pteridines useful as protein kinase inhibitors
    • S. Patent No. 8,067,450: Thiazolidinedione analogues for the treatment of metabolic diseases
    • S. Patent No. 7,767,816: Azaindoles useful as inhibitors of janus kinases
    • S. Patent No. 7,563,795: Phenyl-piperazine derivatives as modulators of muscarinic receptors
    • U.S. Patent No. 7,446,112: Modulators of muscarinic receptors

News & Resources


Seminars & Events

  • Biotech and the Proprosed §101 Legistlation, ABA Biotech Section, July 24, 2019.


  • Michigan Super Lawyers, Recognized as a Rising Star, 2013-2015